| 000 | 01813 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517233715.0 | ||
| 264 | 0 | _c20200116 | |
| 008 | 202001s 0 0 eng d | ||
| 022 | _a1096-9071 | ||
| 024 | 7 |
_a10.1002/jmv.25287 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aElbaz, Tamer | |
| 245 | 0 | 0 |
_aEfficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. _h[electronic resource] |
| 260 |
_bJournal of medical virology _c02 2019 |
||
| 300 |
_a272-277 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Observational Study | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCarbamates |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xadverse effects |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aPyrrolidines |
| 650 | 0 | 4 |
_aRibavirin _xadministration & dosage |
| 650 | 0 | 4 |
_aSofosbuvir _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 700 | 1 | _aAbdo, Mahmoud | |
| 700 | 1 | _aOmar, Heba | |
| 700 | 1 | _aHassan, Essam A | |
| 700 | 1 | _aZaghloul, Amr M | |
| 700 | 1 | _aAbdel-Samiee, Mohamed | |
| 700 | 1 | _aMoustafa, Ahmed | |
| 700 | 1 | _aQawzae, Abdallah | |
| 700 | 1 | _aGamil, Mostafa | |
| 700 | 1 | _aEsmat, Gamal | |
| 773 | 0 |
_tJournal of medical virology _gvol. 91 _gno. 2 _gp. 272-277 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/jmv.25287 _zAvailable from publisher's website |
| 999 |
_c28760057 _d28760057 |
||